Acelrx pharmaceuticals announces publication of results from a clinical study assessing use of sufentanil sublingual tablet for painful radiofrequency microneedling procedures

Study results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone hayward, calif. , march 31, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study evaluating the use of a sufentanil sublingual tablet (sst) 30 mcg for management of pain of radiofrequency ("rf") microneedling of the face or abdomen.
ACRX Ratings Summary
ACRX Quant Ranking